The rise of Sildenafil initially sparked a surge for pharma, but recent changes present a murky outlook for shareholders. Generic versions are eroding earnings, and persistent litigation add further risk to the https://larissagzof040325.get-blogging.com/41613169/sildenafil-and-pharma-a-risky-investment